Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

ablynx nv - caplacizumab - purpura, trombozės thrombocytopenic - antitromboziniai vaistai - cablivi fluorouracilu ir folino suaugusiųjų patiria epizodas įsigijo trombozinių thrombocytopenic purpura (attp), kartu su plazmos keistis ir immunosuppression.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

sanofi b.v. - avalglucosidase alfa - glikogeno kaupimo ligos ii tipas - kiti virškinimo trakto ir metabolizmo produktus, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - kiti virškinimo trakto ir metabolizmo produktus, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - imuninės serumai ir imunoglobulinai, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.